Cargando…
NFB-05. AN UNUSUAL PRESENTATION OF RECURRENT LANGERHANS CELL HISTIOCYTOSIS OF THE CRANIOFACIAL BONES IN A PATIENT WITH NEUROFIBROMATOSIS TYPE I
Neurofibromatosis type 1 (NF1), predisposes patients to benign and malignant tumors due to lack of suppression of the mitogen activated protein kinase (MAPK) signaling pathway. Langerhans cell histiocytosis (LCH) manifests in numerous ways, from localized lesions to multisystem organ involvement sec...
Autores principales: | Chaffee, Blake, Judd, Alexis, Rush, Sarah, Wright, Erin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715405/ http://dx.doi.org/10.1093/neuonc/noaa222.609 |
Ejemplares similares
-
NFB-14. PSYCHOSOCIAL OUTCOMES IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 AND PLEXIFORM NEUROFIBROMAS
por: Damodharan, Sudarshawn, et al.
Publicado: (2020) -
NFB-08. PHASE II STUDY OF AXITINIB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS
por: Phadnis, Sheetal, et al.
Publicado: (2020) -
NFB-13. TRAMETINIB FOR PLEXIFORM NEUROFIBROMA AND RECURRENT LOW-GRADE GLIOMA
por: Sato, Aimee, et al.
Publicado: (2020) -
NFB-18. IMMUNE FUNCTION IN CHILDREN TREATED WITH TRAMETINIB
por: Moukhaiber, Perla, et al.
Publicado: (2020) -
NFB-02. TREATMENT OF PAIN AND TUMOR GROWTH IN NF2
por: Hemenway, Molly, et al.
Publicado: (2020)